PUBLISHER: The Business Research Company | PRODUCT CODE: 2087363
PUBLISHER: The Business Research Company | PRODUCT CODE: 2087363
Animal testing and non-animal alternative testing refer to the range of scientific methods used to evaluate the safety, efficacy, and biological effects of drugs, chemicals, cosmetics, and medical treatments. Animal testing involves the use of living animals to study disease mechanisms and predict human responses, while non-animal alternative testing utilizes advanced approaches such as in vitro cell cultures, computer-based models, and organ-on-chip technologies to achieve similar objectives without the use of animals. The combined purpose of these approaches is to ensure reliable and accurate testing outcomes while balancing scientific advancement, ethical considerations, and regulatory requirements.
The animal testing and non-animal alternative testing market consists of revenues generated by entities (organizations, sole traders and partnerships) that provide testing services, experimental models and related scientific validation services including both animal-based testing and non-animal alternative testing methods for research, safety evaluation and regulatory compliance.
The global animal testing and non-animal alternative testing market was valued at $12,420.0 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 4.00%.
Increasing Pharmaceutical R&D Spending
During the historic period, the animal testing and non-animal alternative testing market was driven by increasing pharmaceutical R&D spending. As pharmaceutical and biotechnology companies intensified efforts to develop innovative drugs, vaccines, and biologics to address complex diseases, investment in research and development activities expanded substantially across global healthcare systems. Animal testing and emerging non-animal alternative testing methods, such as in vitro assays, organ-on-chip systems, and computational toxicology models, play a crucial role in assessing biological responses to new compounds during these early research phases. For instance, in 2023, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), a U.S.-based pharmaceutical industry association, its member companies invested approximately $100.8 billion in research and development activities worldwide, with R&D accounting for about 19.1% of total sales among member firms. Therefore, the animal testing and non-animal alternative testing market was driven by increasing pharmaceutical R&D spending during the historic period.
AI-Powered Biosimulation Supports Regulatory-Ready Non-Animal Research Approaches
Key companies in the animal testing and non-animal alternative testing market are increasingly focusing on advanced computational modeling and AI-enabled biosimulation technologies to reduce reliance on traditional animal-based preclinical studies while maintaining regulatory confidence and scientific accuracy. These innovations emphasize model-informed drug development approaches that integrate predictive analytics, mechanistic modeling, and new approach methodologies (NAMs) to accelerate drug discovery, improve safety assessment, and support ethical research practices. For instance, in April 2025, Certara, Inc., a US-based biosimulation and drug development technology company, launched Non-Animal Navigator, a strategic solution designed to help biopharmaceutical companies transition away from animal testing in line with the U.S. Food and Drug Administration's roadmap for reducing animal testing in preclinical safety studies. The solution provides regulatory guidance and integrates AI-enabled biosimulation tools, including the Simcyp Simulator platform for physiologically based pharmacokinetic (PBPK) modeling, to support predictive evaluation of biologics such as monoclonal antibodies. By combining in vitro data, biosimulation models, real-world evidence, and expert toxicology insights, the Non-Animal Navigator enables pharmaceutical companies to design compliant preclinical strategies, accelerate development timelines, and reduce costs while advancing the adoption of non-animal testing methodologies.
The global animal testing and non-animal alternative testing market is highly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 1.67% of the total market in 2024.
Animal Testing And Non-Animal Alternative Testing Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global animal testing and non-animal alternative testing market.
Where is the largest and fastest-growing market for animal testing and non-animal alternative testing? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The animal testing and non-animal alternative testing market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider animal testing and non-animal alternative testing market; and compares it with other markets.